265 related articles for article (PubMed ID: 32747215)
1. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
Myers TR; McNeil MM; Ng CS; Li R; Marquez PL; Moro PL; Omer SB; Cano MV
Vaccine; 2020 Sep; 38(40):6291-6298. PubMed ID: 32747215
[TBL] [Abstract][Full Text] [Related]
2. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
[TBL] [Abstract][Full Text] [Related]
3. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.
Hansen J; Zhang L; Klein NP; Robertson CA; Decker MD; Greenberg DP; Bassily E; Baxter R
Vaccine; 2017 Dec; 35(49 Pt B):6879-6884. PubMed ID: 28941623
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
5. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
Haber P; Moro PL; Ng C; Dores GM; Perez-Vilar S; Marquez PL; Cano M
Vaccine; 2020 Feb; 38(6):1476-1480. PubMed ID: 31883809
[TBL] [Abstract][Full Text] [Related]
6. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
7. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
8. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
[TBL] [Abstract][Full Text] [Related]
9. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
11. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.
Perez-Vilar S; Dores GM; Marquez PL; Ng CS; Cano MV; Rastogi A; Lee L; Su JR; Duffy J
Vaccine; 2022 Jan; 40(2):247-254. PubMed ID: 34887130
[TBL] [Abstract][Full Text] [Related]
12. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System.
Zheteyeva Y; Moro PL; Yue X; Broder K
Am J Obstet Gynecol; 2013 Jun; 208(6):478.e1-6. PubMed ID: 23453881
[TBL] [Abstract][Full Text] [Related]
13. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
14. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
15. Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra
Kim HS; Engel S; Neveu D; Thollot Y; Oster P; Yang K
Infect Dis Ther; 2021 Mar; 10(1):399-409. PubMed ID: 33439463
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
[TBL] [Abstract][Full Text] [Related]
17. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
[TBL] [Abstract][Full Text] [Related]
18. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
McNeil MM; Paradowska-Stankiewicz I; Miller ER; Marquez PL; Seshadri S; Collins LC; Cano MV
Vaccine; 2019 Oct; 37(44):6760-6767. PubMed ID: 31548014
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
Moro PL; Woo EJ; Marquez P; Cano M
Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
